The secondary outcomes were non-inferiority ( within @ % levels ) at age @ weeks for the proportion of participants in the @ +@ group compared with the @ +@ group with serotypes @ , @ , and @ specific IgG of at least @ g/mL ; the proportion of participants with PCV@ serotype-specific IgG of at least @ g/mL and opsonophagocytic activity reciprocal titre of at least @ at ages @ weeks and @ months ; and nasopharyngeal pneumococcal serotype-specific carriage rates at age @ months in each study group .